I'm LongbridgeAI, I can summarize articles.Eli Lilly (LLY) fell 6.44% this week to close at $1,174.61. The S&P 500 gained 0.49%, so Lilly lagged the benchmark by roughly 6.93 percentage points. Monday (Aug 24) opened at $1,262.14 and ended at $1,246.93, Tuesday (Aug 25) touched $1,264.73 intraday before rolling over, and by Wednesday (Aug 26) the decline widened to a $1,189.41 close. Friday (Aug 28) marked the week’s low at $1,162.93, with the stock settling at $1,174.61. The week’s amplitude was 8.
The Week
Eli Lilly (LLY) fell 6.44% this week to close at $1,174.61. The S&P 500 gained 0.49%, so Lilly lagged the benchmark by roughly 6.93 percentage points. Monday (Aug 24) opened at $1,262.14 and ended at $1,246.93, Tuesday (Aug 25) touched $1,264.73 intraday before rolling over, and by Wednesday (Aug 26) the decline widened to a $1,189.41 close. Friday (Aug 28) marked the week’s low at $1,162.93, with the stock settling at $1,174.61. The week’s amplitude was 8.07%, a pullback from record levels with widening swings.
Key Events
The news this week ran along two lines. In the obesity and diabetes franchise, a real-world study linked Zepbound to lower healthcare costs in adults over 55 with obesity, and the FDA approved Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes. Reports framed the $9.94 billion Mounjaro franchise as winning a heart-risk label. On the competition and commercial side, some employers reportedly declined to cover weight-loss drug costs, Lilly’s cost-saving study did not factor in Zepbound’s price, Novo Nordisk’s oral Wegovy application was accepted by China’s regulator, and Novo faced a lawsuit related to the obesity market. The White House was also reported to be close to new drug pricing deals with biotechs. Several fund managers added or trimmed Lilly positions, but these were routine portfolio adjustments.
Analyst Ratings
Across 32 covering institutions, 18 rate the stock buy, 6 rate it over, 4 hold, 1 under, 1 sell, and 2 have no opinion. The consensus rating is buy, and the consensus target is $1,315.04, implying roughly 11.96% upside from the current price. Individual targets range from $850 to $1,600, a wide spread that points to real disagreement. Lilly ranks first within its industry, ahead of 204 peers, where the average coverage count is 6 and the median is 5.
The Week Ahead
Macro data comes thick next week: Dallas Fed manufacturing activity on Monday (Aug 31), S&P Global manufacturing PMI final, ISM manufacturing PMI and JOLTS job openings on Tuesday (Sep 1), then ADP private payrolls, factory orders and EIA crude inventories on Wednesday (Sep 2). On the company side, Lilly’s third-quarter fiscal 2026 earnings are scheduled for Oct 29, with estimates of $9.2466 EPS on $22.2 billion in revenue. Watchpoints carried over from this week include the White House drug pricing follow-through, Novo’s oral Wegovy progress in China, and how quickly the Mounjaro heart-risk label translates into commercial uptake.
In Short
Lilly’s week was defined by a gap between product news and price action. Zepbound’s cost study and Mounjaro’s FDA approval and heart-risk label were positives, yet the stock dropped 6.44% and lagged the S&P 500 by almost 7 percentage points. The analyst picture leans constructive—consensus rating buy, target above spot, top industry rank—but the $850 to $1,600 target range is unusually wide, signalling a wide dispersion of views. Valuation remains full at 41.55x P/E and 32.76x P/B. The story to watch is whether drug-pricing policy filters through into coverage and cost pressure, and whether Lilly’s obesity and diabetes commercial data keep delivering.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.